EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands  ¹     William Sandborn  ²     Laurent Peyrin-Biroulet  ³     Peter Higgins  ⁴     Fumihito Hirai  ⁵     Vipul Jairath  ⁶     Geert R. D'Haens  ⁷     Maria T. Abreu     Ruth Belin     Elisa Gomez Valderas     Debra Miller     April Naegeli     Vipin Arora     Paul Pollack     Jay Tuttle     Toshifumi Hibi    
¹ Icahn School of Medicine at Mount Sinai,New York,United States
² University of California San Diego,La Jolla,United States
³ Nancy University Hospital Inserm U 954,Vandoeuvre les Nancy,France
⁴ University of Michigan,Ann Arbor,United States
⁵ Fukuoka University Chikushi Hospital,Chikushino,Japan
⁶ Western University,London,Canada
⁷ Univers

Session
IBD: Clinical trials II

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)